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1. Introduction 
Peripheral neuropathy describes a range of degenerative processes that affect the peripheral 
nervous system and are largely untreatable. These neuropathies affect both sensory and 
motor fibers and include diabetic neuropathy, chemical neuropathy, post-herpetic neuralgia 
and peripheral nerve injury. Other causes of neuropathy include alcoholism, nutritional 
deficits, Guillian-Barre syndrome, AIDS related neuropathy and neuropathy caused by 
toxins such as heavy metals. Current treatments focus on pain management and on 
microsurgical intervention such as nerve grafting (Federici and Boulis 2009). Therapies that 
focus on promoting axon growth and regeneration subsequent to peripheral nerve 
degeneration or injury are suboptimal. 
1.1 Peripheral nerve injury 
Damage to peripheral nerves results in demyelination and axonal degeneration. Axonal 
degeneration can happen in several ways. Wallerian degeneration happens when the 
continuity of the nerve fibre is interrupted through traumatic, toxic, ischemic or metabolic 
events (Dubovy 2011). In neurodegenerative processes, there is progressive degeneration of the 
axons towards the cell body which remains intact over a longer period of time. This degenerative 
process is referred to as distal axonopathy or dying back axonal degeneration (Hoke 2006). 
Research on both super oxide dismutase 1 (SOD1) mice and on patients suffering from ALS have 
found degeneration of neuromuscular junctions prior to the loss of motor neurons. This indicated 
that ALS is considered to be a distal axonopathy (Fischer, Culver et al. 2004).  
The peripheral nervous system has the ability to regenerate axons in response to an injury. 
Axonal stumps possess the ability to regenerate and grow in response to Schwann cells and 
their basal lamina (Fischer, Culver et al. 2004). Macrophages and Schwann cells phagocytose 
the myelin debris (Fansa and Keilhoff 2003) that results from the injury. Fibroblasts and 
Schwann cells provide a matrix for axonal regrowth. They secrete neurotrophic factors that 
support and enhance neuron survival (Ide 1996). In Wallerian degeneration Schwann cells 
carry out the first step in myelin sheath evacuation by myelin fragmentation. The degraded 
myelin is phagocytosed by macrophages for full myelin clearance (Stoll, Griffin et al. 1989). 
This is an important step prior to nerve regeneration. Schwann cells in the region of the 
damaged neurons secrete a number of growth factors such as glial-cell derived neurotrophic 
factor (GDNF), brain derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1) 
and nerve growth factor (NGF) (Funakoshi, Frisen et al. 1993). 
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Fig. 1. Comparison of Wallerian and “Dying Back” degeneration in neurons. 
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Nerve regeneration starts at the node of Ranvier near the proximal stump. The basal lamina 
that remains post-injury, which surrounds the axon and the Schwann cells, acts as a conduit 
or tube for the regenerating axon. The damaged nerve stump distal to the injury supports 
regeneration by assisting regenerating sprouts to extend in the direction of the distal stump 
(Hoke 2006). 
The next step in axonal regeneration occurs when the axons enter the distal stump. They 
have to grow over a long distance in an environment that is considerably different from the 
embryonic one originally encountered. The regenerating nerve also has to remyelinate. The 
last step to complete the regenerative process is for the axon to find and reinnervate their 
original targets be they muscle or sensory organs (Abrams and Widenfalk 2005). 
1.1.1 Therapeutic targets 
A damaged peripheral nerve can be divided into a number of parts. Each one needs to be 
considered individually as a therapeutic target (Figure 2).  
 
 
Fig. 2. Identification of the four different parts of a damaged neuron. 
The first part is the nerve cell body and the proximal stump. The nerve cell body is 
necessary for providing the metabolic machinery to support axonal growth. Trauma and 
neurodegenerative processes affect the axon but can also damage the nerve cell body. 
Treatments that aim to protect nerve cell body health after injury have been aimed at 
neuroprotection and trying to minimise cell death. Neurotrophic factors mediate neuronal 
survival and factors such as nerve growth factor (NGF) (Levi-Montalich, 1987), glial derived 
neurotrophic factor (GDNF) (Lewis, Neff et al. 1993), IGF-1 (Henderson, Phillips et al. 1994) 
and vascular endothelial growth factor (VEGF) (Storkebaum, Lambrechts et al. 2004) have 
been employed for their neuroprotective effects. Other factors that are feasible in 
minimising nerve cell body death are anti-apoptotic factors. The X-linked inhibitor of 
apoptosis protein (XIAP) mediated protection of motor neurons as shown in in vitro models 
of ALS and in diabetic neuropathy (Garrity-Moses, Teng et al. 2004). Other anti-apoptotic 
factors such as Bcl-2 and Bcl-xL which prevent apoptosis both in vitro and in vivo 
(Yamashita, Mita et al. 2001; Matsuoka, Ishii et al. 2002; Yamashita, Mita et al. 2003; Garrity-
Moses, Teng et al. 2005) are attractive for neuroprotection A problem associated with 
therapies that solely act on the proximal stump of a damaged nerve is the growth of axons 
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into this milieu without being able to leave it. Excessive neuronal growth can lead to 
neuromas which prevent reinnervation of the distal stump and cause pain. 
The second part of the injured peripheral nerve that needs to be considered is the gap. The 
success of the axon regrowth depends on the severity of the injury, the distance that needs 
to be bridged and how soon any intervention occurs post-injury (Midha, Munro et al. 2005; 
Weber and Mackinnon 2005). Nerve grafts assist in directing nerve regrowth. Grafting along 
with gene therapy has been used to assist in this process. The principle was proven by 
adenoviral transduction of nerve grafts (Blits, Dijkhuizen et al. 1999). In this experiment, 
sections of peripheral intercostal nerves were transduced with adenovirus expressing LacZ 
as a reporter gene. These nerves were then grafted into transacted sciatic nerves, avulsed 
neutral root, hemi-sected spinal cord and intact brain. Expression of LacZ could still be 
detected up to 7 days post-implantation. 
The third part of the injured nerve is the distal stump and the neuromuscular junction. The 
distal stump of the damaged nerve provides support for neuronal regrowth via the release 
of stimulatory factors. These factors assist generating nerve sprouts to extend towards the 
target tissue (Abrams and Widenfalk 2005). One therapeutic strategy is to silence the 
expression of genes that inhibit nerve regrowth. Silencing the expression of the components 
of the inhibitory signalling cascade, using siRNAs, such as p75NTR, NgR and RhoA was 
shown to promote neurite outgrowth in cultured DRGs (Ahmed, Dent et al. 2005). This is a 
viable strategy for peripheral nerve injury therapy (Abrams and Widenfalk 2005). 
The fourth and final part of a damaged peripheral nerve is the environment in which it is 
situated. The environment surrounding a damaged peripheral nerve is a target for ex vivo 
gene therapy. Stem cells that have been genetically engineered to enhance neurotrophic 
factors are a therapeutic option for injured peripheral nerves that has received considerable 
attention (Tohill and Terenghi 2004). Periaxonal grafts of nerve stem cells that secrete GDNF 
have been found to assist in providing a supportive environment for nerve regeneration 
(Deshpande, Kim et al. 2006).  
2. Gene and cell therapy  
Gene and cell therapies have the potential to be effective in peripheral neuropathy 
treatment. A number of factors need to be taken into account to allow this to happen. The 
correct vector (viral or non-viral) or cell type has to be chosen for the neuropathy based on 
vector or cell tropism. The vector tropism will help determine the method of delivery of the 
vector. Delivery will either be directly into the site of injury or degeneration, or remote from 
the site of injury. In the case of remote delivery the choice of therapeutic will depend on its’ 
ability to cross the blood nerve barrier, in the case of AAV-9, or its’ ability to be moved via 
retrograde transport from, for example, an intramuscular injection to the site of nerve injury. 
The therapeutic gene delivered using a vector has to be selected for optimum effect and if 
cell therapy is used whether the cells are engineered to secrete a neurotrophic factor. 
2.1 Gene therapy vectors 
Gene therapy vectors can be divided into viral and non-viral vectors based on their origin. 
The intent is to deliver a therapeutic gene to the affected area and affect a positive outcome. 
A variety of different viruses can be converted to viral vectors with different affinities for 
the peripheral nervous system. For example, herpes vectors have a natural tropism for the 
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neurons of the Dorsal Root Ganglia (DRG) (Fink, Ramakrishnan et al. 1996). Similarly, a 
wide variety of methods exist for non-viral gene delivery. These can be engineered for 
enhanced gene delivery to the nerve. 
2.1.1 Non-viral vectors 
Non-viral vectors can include plasmid DNA containing the therapeutic gene of interest, 
cationic and polycationic polymers. The major advantage these have over viral vectors is 
their safety. The major disadvantage for gene transfer in the nervous system is they have a 
very low efficiency when compared to viral vectors (Costantini, Bakowska et al. 2000; Hsich, 
Sena-Esteves et al. 2002). The plasmid DNA vector can be delivered unmodified or with a 
targeting molecule attached to improve delivery. One such targeting molecule it the tet 
peptide developed by our research group (Liu, Teng et al. 2005). This peptide was identified 
based on its’ homology to the tetanus toxin and it enhances neurotropism. This peptide was 
used by Park and colleagues to successfully target plasmid DNA the neural cells and DRG 
cells in vitro (Park, Lasiene et al. 2007) and in vivo via an injection into lateral ventricle of 
mice. The tet-1 complexed plasmid was found to target adult neural progenitor cells (NPCs) 
(Kwon, Lasiene et al. 2010).  
2.1.2 Viral vectors 
Viral vectors consist of viruses whose genome has been modified to carry the therapeutic 
gene. The genome is usually altered such that the vector is unable to replicate. In the 
peripheral nervous system there are a number of different viral vectors that have been used; 
Adenoviral vectors (Ad), Adeno associated vectors (AAV), Herpes simplex virus (HSV) type 
1 and Lentiviral vectors.  
2.1.2.1 Adenoviral vectors 
Adenoviral vectors have been extensively used in gene therapy research. They have been 
shown to transduce post-mitotic dorsal root ganglions (DRGs), neurons (Glatzel, Flechsig et 
al. 2000) and Schwann cells (Shy, Tani et al. 1995; Dijkhuizen, Pasterkamp et al. 1998; 
Sorensen, Haase et al. 1998). They are non integrating vectors and therefore are limited to 
short-term expression which is a disadvantage. Ad vectors also have the drawback of 
eliciting an immune response which is an undesirable attribute in a therapeutic agent. 
2.1.2.2 Adeno-associated vectors (AAV) 
Adeno-associated vectors (AAV) are a very attractive vector for gene therapy. AAV vectors 
have long term and stable transgene expression and also efficiently transduce post-mitotic 
neurons. A disadvantage of AAV vectors is that there is a limit to the size of the transgene it 
can carry. This can make it unsuitable for larger transgenes. There are a number of AAV 
serotypes that have different tropisms for neural cells. AAV2 has been demonstrated to 
transduce DRGs, Schwann cells and fibroblasts (Fleming, Ginn et al. 2001). AAV9 has the 
ability to transduce a number of different neural cells types (Foust, Nurre et al. 2009). A 
study by our research group in mice showed that different AAV serotypes had different 
longitudinal spread within the spinal cord (Snyder, Gray et al. 2011) suggesting that similar 
differences in spread exist within the peripheral nervous system exist. 
2.1.2.3 Herpes Simplex Virus (HSV) type 1 
Herpes Simples Virus (HSV) type 1 is naturally neurotrophic. HSV-1 produces a lytic 
infection of skin cells and then migrates to the nerve processes. It is then transported in 
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retrograde fashion to the sensory cell body of DRGs (Pradat and Mallet 2003). The ability of 
HSV type 1 to transduce sensory neurons makes it an ideal choice for neuropathies affecting 
sensory neurons (Glorioso and Fink 2004). The main disadvantage of HSV type 1 vectors is 
the immune response elicited against the virus proteins and the cell toxicity of the virions 
(Pradat and Mallet 2003).  
2.1.2.4 Lentiviral vectors 
Lentiviral vectors are also naturally neurotrophic (Fleming, Ginn et al. 2001). They integrate 
into the host genome which makes the expression of the carried transgene both stable and 
long-term (Blits, Boer et al. 2002; Hu, Leaver et al. 2005). Lentiviral vectors have limited 
immunogenicity and can accommodate a larger transgene than AAV (Federici and Boulis 
2009). The modification of the lentiviral coat, which is termed pseudotyping, to enhance its 
transduction ability has been extensively studied. Pseudotyping of lentivirus with the 
rabies-G glycoprotein exploits the natural uptake of the rabies virus by axon terminals at 
neuromuscular junctions. This has been used to improve motor neuron gene delivery 
(Mazarakis, Azzouz et al. 2001; Cronin, Zhang et al. 2005)  
 
Vector Advantages Disadvantages 
Adenoviral Easily transduces post-
mitotic cells 
Short expression time 
Immunogenic 
HSV type 1 Naturally neurotrophic 
Retrogradely transported 
Naturally immunogenic 
AAV Integrates and gives 
prolonged expression.  
A number of different 
serotypes available 
Small cloning capacity 
Lentiviral Stable, integrated 
expression 
Retrogradely transported 
Large cloning capacity 
Integration mutagenesis 
Table 1. Comparison of different viral vectors. 
2.1.3 Transport of vectors 
The ability of vectors to be transported in a retrograde manner into the nervous system 
makes them more amenable for gene therapy of peripheral neuropathies. It allows the 
therapy to be administered at a site distant from and less invasive for the targeted area. 
Although Ad and AAV vectors are not naturally neurotrophic, they both have the ability to 
be transported in a retrograde manner and infect both sensory and motor neurons. A 
number of research groups have shown Ad vectors to be transported in a retrograde manner 
after intramuscular and intraneural injections (Finiels, Ribotta et al. 1995; Ghadge, Roos et al. 
1995; Boulis, Bhatia et al. 1999). It is also possible to modify these vectors to enhance their 
affinity for neurons and as a consequence increase the rate of retrograde transport. 
Inoculation with botulinum toxin was found to enhance Ad vector transport and increase 
expression of the transgene in motor neurons (Millecamps, Mallet et al. 2002). 
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Different AAV serotypes have been shown to be transported in a retrograde fashion 
following both intramuscular and intraneural delivery (Boulis, Noordmans et al. 2003; 
Kaspar, Llado et al. 2003; Kaspar, Vich et al. 2004). A number of research groups have been 
working on improving the affinity AAV vectors have for neural cells. One means of 
achieving this is to modify the protein coat of the vector to incorporate neurotrophic 
peptides to enhance its’ therapeutic effect. Peptides that mimic the binding capacity of the 
tetanus toxin, the NMDA receptor and peptides that mimic the activity of dynein have been 
inserted into the protein coat of AAV2 vectors to improve their neurotropism (Xu, Ma et al. 
2005; Federici, Liu et al. 2007).  
HSV-1 is a viral vector that is naturally neurotrophic. Recombinant HSV-1 has demonstrated 
the ability to transduce both motor and sensory neurons after intramuscular and 
subcutaneous delivery (Yamamura, Kageyama et al. 2000; Glorioso and Fink 2004). 
However, HSV mediated gene expression is transient. The lack of durability in expression 
impedes the application of HSV mediated gene delivery to chronic and ongoing 
neuropathies. 
There is extensive research to show that lentiviral vectors have the ability to be transported 
in a retrograde manner. In a similar manner to AAV, the lentiviral vector can be engineered 
to enhance its’ effect. The rabies virus is transported axonally via a neuromuscular junction. 
A lentiviral vector that is pseudotyped with the rabies G protein will have increased axonal 
transport and will reach the spinal cord motor neurons (Cronin, Zhang et al. 2005). 
Transduction of motor neurons in the lumbar spinal cord by a rabies-G pseudotyped 
lentiviral vector has been shown after peripheral administration intramuscularly 
(Mazarakis, Azzouz et al. 2001). Our research group has published data demonstrating that 
a pseudotyped human immunodeficiency virus type 1 (HIV-1) based lentiviral vector was 
capable of transducing specific cells types and increasing retrograde axonal transport 
(Federici, Kutner et al. 2007).  
2.2 Cell therapy 
The use of cell therapy in peripheral neuropathy especially peripheral nerve injury has been 
the focus of research. The peripheral nervous system has the ability to regenerate axons and 
reinnervate end organs. However, this can be problematic in the case of chronic denervation 
of distal nerves.  
2.2.1 Schwann cells (SC) 
Schwann cells (SC) have been shown to support peripheral nerve repair. They achieve this 
by changing their phenotype from myleinating to growth supporting (Shy, Shi et al. 1996; 
Mirsky and Jessen 1999). If the Schwann cells themselves are denervated for a prolonged 
period of time their ability to support peripheral nerve regrowth is impaired and inhibited 
(de Medinaceli and Rawlings 1987; Fu and Gordon 1995). One therapeutic option is to 
supplement or replace the deprived Schwann cells with healthy ones from another nerve. 
Infusion of healthy Schwann cells has been able to support regeneration and remyleination 
of both the spinal cord (Takami, Oudega et al. 2002; Pearse, Pereira et al. 2004) and in 
peripheral nerves (Guenard, Kleitman et al. 1992). The limiting factor in this is the number 
of Schwann cells obtainable from this source. There is also the fact that obtaining the 
Schwann cells from nerve tissue itself causes damage.  
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2.2.2 Neural stem cells (NSCs) 
Neural stem cells (NSCs) have the ability to differentiate into neurons, astrocytes and 
oligodendrocytes (Parker, Anderson et al. 2005). They can also be induced to differentiate 
into Schwann cells (Blakemore 2005). NSCs secrete the growth factors that help support 
nerve regeneration (Heath 2000). They can be sourced from either fetal, adult or a non-
neuronal tissue source. Implantation of NSCs has been shown to promote axonal 
regeneration and to form Schwann cell like peripheral myelin sheaths (Blakemore 2005). 
Therefore NSCs transplanted into a peripheral nerve injury site can help overcome the issue 
of limited sources of healthy Schwann cells and they can also promote peripheral nerve 
regeneration. The fact that NSCs can be grown and amplified in vitro is an added advantage. 
NSCs have been used in sciatic nerve injury repair. 
2.2.3 Mesenchymal stem cells (MSC) 
Mesenchymal stem cells (MSC) are adult derived stem cells that have the ability to 
differentiate down three lineages; adipogenic, chondrogenic and osteogenic. There have 
been a number of studies that show MSCs possess immunomodulatory properties in vitro on 
cell populations of both passive and adaptive immunity(Uccelli, Moretta et al. 2006). A 
study in a mouse model of experimental autoimmune encephalomyelitis (EAE), which is a 
model for human multiple sclerosis (MS), injected MSCs on one side of the brain and 
induced peripheral T cell tolerance to myelin proteins. This reduced the migration of 
pathogenic T cells to the CNS. On the other side of the brain the MSCs were found to 
preserve axons and reduce myelination (Bai, Lennon et al. 2009; Constantin, Marconi et al. 
2009). Injection of MSCs into the spinal cord of transgenic SOD1 (G93A) mice, a model for 
ALS, was found to improve motor neuron survival, prolong life and improve motor 
performance (Vercelli, Mereuta et al. 2008). There have been a number of studies looking at 
the therapeutic effect of MSCs in peripheral nerve injury models. In a rat model of sciatic 
nerve injury MSCs were injected into the lumber DRG. The MSCs were found to have an 
analgesic effect affecting the expression of neuropetides galanin and neuropeptide Y (NPY) 
(Coronel, Musolino et al. 2009). Treatment of damaged nerves directly with MSCs has also 
been demonstrated to be effective. In a rat model of facial nerve injury MSCs were applied 
to a transected facial nerve after anastomosis. Results showed that the MSC treated nerve 
did better in terms of axonal organisation and myelin thickness when compared to nerves 
that had only been sutured (Satar, Karahatay et al. 2009) In another study MSCs were 
injected subepineurally one week after sciatic nerve injury in rabbits. Nerves that were 
grafted with MSCs showed better functional recovery, and improved nerve regeneration 
(Duan, Cheng et al. 2011) 
 
Cell Type Source Advantages 
Schwann Cells Nerve tissue Autologous source 
NSC Fetal or adult Neural in origin 
MSC Adult tissues (bone marrow, 
adipocytes) 
Ability to differentiate into 
different lineages 
Home to injury site 
Table 2. Comparison of different cell types. 
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3. Peripheral nerve disorders 
3.1 Diabetic neuropathy 
Diabetic neuropathy is a complication of both insulin-dependent and insulin-independent 
diabetes mellitus. There are a number of possible contributing factors to the development of 
diabetic neuropathy such as oxidative stress, non-enzymatic glycation of nerve endings and 
mitochondrial damage (Mata, Chattopadhyay et al. 2006). A lack of or a reduction in 
neurotrophic factor levels is also considered a possible factor. Research has demonstrated 
that supplementation of neurotrophic factors can help delay the progression of diabetic 
neuropathy and other polyneuropathies. 
Both nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) have had 
therapeutic success in animal models of diabetic neuropathy. A HSV based vector 
expressing NGF was used to transduce dorsal root ganglion of diabetic mice. Results 
showed that it prevented loss of sensory nerve action potential (Goss, Goins et al. 2002). 
Subcutaneous delivery of VEGF in an HSV vector was transported in a retrograde manner 
to the DRGs and was found to preserve nerve fibres in diabetic mice (Chattopadhyay, 
Krisky et al. 2005). Placental growth factor (PlGF) is a member of the VEGF family. PlGF-2 
has been found to display neurotrophic actions acting through neuropillin – 1 (NP-1) in 
DRGs in vitro. In vivo, PlGF-2 plasmid was injected with electroporation into the skeletal 
muscle of diabetic mice. Results showed a restoration of sensory deficits in these diabetic 
mice that was mediated via NP-1 (Murakami, Imada et al. 2011). Another study used a 
regulatable HSV vector to deliver erythropoietin (EPO) to diabetic mice. The HSV vector 
expression was controlled using the tet-on system which means EPO was expressed in 
response to presence of doxycycline (DOX). Mice were inoculated via their footpad and 
were administered DOX on a controlled basis. This regulated expression of EPO was found 
to be effective in protecting against the progression of neuropathy in these diabetic animals 
(Wu, Mata et al. 2011).  
There is currently a clinical trial underway for diabetic neuropathy. VM202 which is human 
hepatocyte growth factor encoded in a plasmid. It is a Phase 1/2 open label trial examining 
safety and the effect of dose escalation with the gene therapy being administered via 
intramuscular injection into the calf muscle (www.clinicaltrials.gov , NCT01002235). A 
second phase 2 clinical trial is using zinc finger proteins in the treatment of diabetic 
neuropathy. Zinc finger proteins have the ability to increase expression of endogenous 
genes and can be designed to target specific genes (Davis and Stokoe 2010). In this trail the 
zinc finger protein is targeting VEGF and increasing its expression (www.clinicaltrials.gov, 
NCT01079325). 
3.2 Peripheral nerve injury 
A large number of the existing therapies for peripheral nerve diseases are concentrated on 
the proximal stump of the nerve (Federici and Boulis 2007). The ability of a number of viral 
vectors to be transported in a retrograde manner means they have been utilised to deliver 
neurotrophic factors (Romero, Rangappa et al. 2001; Natsume, Wolfe et al. 2003; Araki, 
Shiotani et al. 2006). In the case of peripheral nerve injury the site of the damaged nerve is 
first identified using current therapies. This has the advantage of exposing the damaged 
proximal stump of the nerve to allow the therapeutic vectors access. The viral vector can be 
engineered to enhance their uptake and retrograde transport. This can help improve their 
therapeutic effect and help prevent further nerve degeneration. Neuro-targeting peptides 
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can be incorporated into the viral coat and into plasmids to enhance vector uptake as 
previously outlined (Federici, Liu et al. 2005; Park, Lasiene et al. 2007; Kwon, Lasiene et al. 
2010).  
An adenoviral vector was used to deliver glial derived neurotrophic factor (GDNF) 
intramuscularly in a chronic constricted nerve injury rat model of peripheral nerve injury. The 
injury to the limb was found to increase mechanical and thermal hypersensitivity. GDNF/Akt 
signalling was lost, particularly, in the distal stump of the sciatic nerve. Ad-GDNF therapy 
was found to restore GDNF/Akt signalling and this was associated with improved 
myelination and behavioural outcomes (Shi, Liu et al. 2011). An Ad vector was also used to 
deliver bone morphogenetic protein 7 (BMP-7) in a rat model of sciatic injury. BMPs promote 
neuronal differentiation and have been implicated in the survival of peripheral nerves (Beck, 
Drahushuk et al. 2001; Guha, Gomes et al. 2004; Schluesener, Meyermann et al. 1995) and in 
this study Ad-BMP-7 improved hind-limb recovery and reduced macrophage activation, nerve 
demyelination and axonal degeneration (Tsai, Pan et al. 2010). 
Stem cells can also be utilised in peripheral nerve injury repair. One group used neural stem 
cells that had been engineered to secrete glial cell-line derived neurotrophic factor (GDNF). 
These cells were administered to the sciatic nerve of rats that had previously received spinal 
cord embryonic stem cell-derived motor neuron transplantation (Deshpande, Kim et al. 
2006). The increased level of expression of GDNF in the sciatic nerve attracted embryonic 
stem cell- derived axons. Theses axons reached the muscle and formed physiologically 
active neuromuscular junctions.  
3.3 Neuropathic pain 
Neuropathic pain is caused by either dysfunction of the CNS, PNS or a primary lesion. This 
can manifest itself as hypersensitivity to pain (hyperalgesia) or as a painful response to a 
stimulus that would not normally cause pain (allodynia). Currently opiates are the mainstay 
of treatment for the majority of chronic pain states (Beutler and Reinhardt 2009). Their use 
has generally improved outcome (Portenoy 1995; Levy 1996) but due to side-effects opiates 
have not been effective in a significant number of patients (Caraceni and Portenoy 1999; 
Weiss, Emanuel et al. 2001). The possibility of delivering a therapeutic gene to alleviate the 
symptoms of pain has been studied in a number of animal models of neuropathic pain as 
well as the possibility of also of modulating both the excitatory and inhibitory pathways of 
pain has also been examined in these disease models (Cope and Lariviere 2006).  
As previously discussed the HSV-1 vector is naturally neurotrophic and it has been utilised 
extensively in sensory neuropathies. Administration of a HSV-1 vector expressing glutamic 
acid decarboxylase (GAD) subcutaneously has been found to alleviate pain in a model of 
spinal nerve ligation. Increased expression of GAD in the DRGs resulted in attenuation of 
the symptoms of mechanical allodynia and thermal hyperalgesia (Hao, Mata et al. 2003). 
GDNF expressed by either a HSV-1 or lentiviral vector has also been found to be effective in 
reversing pain manifestations in spinal nerve ligation pain model. The HSV-GDNF was 
delivered subcutaneously and the lentiviral-GDNF was delivered via intraspinal injections 
(Hao, Mata et al. 2003; Pezet, Krzyzanowska et al. 2006). Treatment with both vectors was 
found to significantly alleviate both thermal and mechanical hyperalgesia symptoms.  
Another focus has been on the opiate system. HSV-1 vectors encoding human proenkephalin 
A, which is an opiate peptide precursor, has been found to have anti-hyperalgesia effects in 
mice models of hyperalgesia (Wilson, Yeomans et al. 1999; Yeomans, Jones et al. 2004).  
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A further possibility is to knockdown expression of gene involved in pain pathways. 
Lentiviral vectors have been used to deliver short hairpin RNAs to knockdown expression 
of a voltage-gated sodium channel (NaV1.8). This ion channel is thought to be involved in 
the pathogenesis of neuropathic pain in DRGs. Delivery of the lentivirus expressing the 
shRNA to primary DRGs was found to knockdown protein and messenger RNA (mRNA) 
levels and to also decrease the NaV1.8 mediated current densities (Mikami and Yang 2005). 
Another study used an AAV vector to deliver a shRNA to knockdown expression of GTP 
cyclohydrolase I (GCHI). Activation of expression of GTPI cyclohydrolase in DRGs has been 
shown to be significantly involved in development and longevity of pain symptoms. The 
shRNA was delivered to the sciatic nerve and expression of the transgene was detected in 
the DRGs. Knockdown of GTP1 cyclohydrolase resulted in a sharp decline in pain 
symptoms in the animal model and also showed reduced microglial activation in the dorsal 
horn which inferred a link between pain relief and reduced inflammation (Kim, Lee et al. 
2009).  
3.4 Motor neuron disease 
Motor neuron diseases, which include amyotrophic lateral sclerosis (ALS) and spinal 
muscular atrophy (SMA), are progressive neurodegenerative diseases that result in 
progressive loss of both upper and lower motor neurons. Both diseases are invariably fatal 
and current therapies are merely palliative. The possibility of gene or cell therapy as a 
therapeutic option for motor neuron disease is being extensively researched.  
Successful gene transfer has been achieved in motor neuron disease by both intramuscular 
(Kahn, Haase et al. 1996, Wang, Lu et al. 2002, Lesbordes, Cifuentes-Diaz et al. 2003) and 
intraneural delivery(Boulis, Noordmans et al. 2003; Boulis, Willmarth et al. 2003). Ex vivo 
gene therapy involving genetic modification of cells that are then transplanted into the 
injured region has also been investigated in relation to motor neuron disease. This has 
involved grafting cells that have to ability to secrete neurotrophic factors. An example of 
this involved the implantation of myoblasts that had been retrovirally transduced with 
GDNF. These cells were implanted into the hindlimb of SOD1 mouse model of ALS. GDNF 
gene delivery was found to prevent motor neuron loss and disease progression (Mohajeri, 
Figlewicz et al. 1999). There is a Phase 2 clinical trial for an ALS therapy currently taking 
place in which neural stem cells are being injected to the spinal cord of ALS patients 
(www.clinicaltrials.gov NCT01348451).  
4. Conclusion 
Peripheral neuropathies in the form of diabetic neuropathy, peripheral nerve injury and 
neuropathic pain are painful and debilitating conditions. Amyotrophic lateral sclerosis 
(ALS) and spinal muscular atrophy (SMA) are not peripheral neuropathies in the strictest 
sense but they are related as disorders of the cells that form the peripheral nerves. Current 
best clinical practise offers drug treatment for pain relief and nerve grafting for damaged 
nerves. These treatments have some success but room for improvement exists.  
Gene and cell therapies have the potential to improve treatment outcomes in these 
peripheral neuropathies. Gene therapy vectors potential to transduce neurons and be 
transported in a retrograde manner has been exploited in animal models of these diseases 
and has shown beneficial effects. Efforts to improve tropism of vectors by pseudotyping and 
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by incorporating neurotrophic peptides into viral coats increase specificity of these vectors 
and reduce the problem of off-target effects. In a similar manner cell therapies can be used 
in these diseases. Cell therapies can be used in an unmodified state where they can effect 
change at the site of injury or can be engineered to secrete a specific factor that will support 
nerve regrowth and repair. 
The movement of potential therapies into clinical trials is ongoing. In the meantime research 
continues to improve and refine understanding of peripheral neuropathies while working 
on therapy concepts to treat these conditions. 
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